drugset / Trial / NCT01578564
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.
Timeline
- Start
- 2012-07
- Primary completion
- 2015-07
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOR-C13 | Protein / enzyme biologic | 1.375 mg/kg | Intravenous |
| Subject | SOR-C13 | Protein / enzyme biologic | 6.12 mg/kg | Intravenous |